Snapshot · Gilead Sciences, Inc. (GILD)

Data as of 2026-10-19T00:21:59.927Z

Fundamentals check

Market cap

$193.7B

P/E (TTM)

-60.1

Gross margin

79.6%

Net margin

-10.6%

ROE

-16.3%

R&D / revenue

19.9%

Dividend yield

2.1%

FCF yield

6.8%

Latest dividend: $0.82/share (ex-date 2026-09-15, quarterly)

Summary

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

How it makes money

Revenue mix, latest fiscal year

• Biktarvy48.7%
• Descovy9.4%
• Genvoya5.1%
• Yescarta5.1%
• Trodelvy4.7%
• Sofosbuvir/Velpatasvir4.3%

Recent Events

• 2026-10-14T12:58:37.000Zpositive

  Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments

  联合开发协议可能提升前景预期，恰逢行业并购热闹，具体影响尚未定型。

  Source: benzinga.com

• 2026-10-14T04:59:04.000Zpositive

  Gilead Sciences, Inc. $GILD Stock Acquired by RHS Financial LLC

  机构增持报道可能反映市场对股价的积极信号，但不构成对价格变动的直接因果结论。

  Source: defenseworld.net

• 2026-10-14T00:00:00.000Zpositive

  Price move: GILD rose 3.8%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-09-10T02:27:06.000Znegative

  Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

  事件日期接近公司消息，市场对会议转录内容的反应可能与股价短期波动相关，无法确定因果关系。

  Source: seekingalpha.com

• 2026-08-18T00:00:00.000Zpositive

  Price move: GILD rose 3.3%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-04T16:01:00.000Znegative

  Gilead Sciences Announces Second Quarter 2026 Financial Results

  财报结果在市场中引发下跌压力的可能性存在，但需结合其他因素判断因果，非确定性结论。

  Source: businesswire.com

• 2026-08-04T00:00:00.000Zpositive

  Price move: GILD rose 3.1%

  GILD 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-03T13:04:42.000Zpositive

  California's highest court rules for Gilead in 'duty to innovate' case

  法院裁决有利于Gilead，或有助于提振情绪，但不应视为对未来业绩的直接因果驱动。

  Source: reuters.com

Analyst view

Avg price target $148.11 from 9 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-10-15SellMercier Johanna(officer: Chief Comm & Corp Aff Officer)3,000 shares
• 2026-10-15SellDickinson Andrew D(officer: Chief Financial Officer)3,000 shares
• 2026-10-01SellO'Day Daniel Patrick(director, officer: Chairman & CEO)3,000 shares
• 2026-10-01SellO'Day Daniel Patrick(director, officer: Chairman & CEO)12,000 shares
• 2026-09-15SellMercier Johanna(officer: Chief Comm & Corp Aff Officer)600 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。